However, there was a second parameter observed in the large adjuvant trials with tamoxifen and the aromatase inhibitors that closely paralleled prevention trials, specifically the ability of these agents to prevent the development of breast cancer in the contralateral breast (Goss et al., 2005; Ruhstaller et al., 2019). This evidence concerns the gene CYP19A1 and breast cancer.